194 related articles for article (PubMed ID: 19255987)
1. Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand.
Roungrong J; Teerawattananon Y; Chaikledkaew U
J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S119-25. PubMed ID: 19255987
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
Borg S; Glenngård AH; Osterborg A; Persson U
Acta Oncol; 2008; 47(6):1009-17. PubMed ID: 18770060
[TBL] [Abstract][Full Text] [Related]
3. Preoperative use of recombinant human erythropoietin in pediatric orthopedics: a decision model for long-term outcomes.
Vitale MG; Roye BD; Ruchelsman DE; Roye DP
Spine J; 2007; 7(3):292-300. PubMed ID: 17482112
[TBL] [Abstract][Full Text] [Related]
4. The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.
Devine EB; Cross JT; Kowdley KV; Sullivan SD
Curr Med Res Opin; 2007 Jun; 23(6):1463-72. PubMed ID: 17559739
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.
Klarenbach S; Manns B; Reiman T; Reaume MN; Lee H; Lloyd A; Wiebe N; Hemmelgarn B; Tonelli M
Cancer; 2010 Jul; 116(13):3224-32. PubMed ID: 20564645
[TBL] [Abstract][Full Text] [Related]
6. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
7. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
Breitscheidel L
J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
[TBL] [Abstract][Full Text] [Related]
8. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
Baron F; Frère P; Fillet G; Beguin Y
Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
[TBL] [Abstract][Full Text] [Related]
10. Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis.
Borget I; Tilleul P; Baud M; Joly AC; Daguenel A; Chouaid C
Lung Cancer; 2006 Mar; 51(3):369-76. PubMed ID: 16388876
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in clinical trials: assessment and utility with special reference to rHuEPO.
Brandberg Y
Med Oncol; 1998 Aug; 15 Suppl 1():S8-12. PubMed ID: 9785331
[No Abstract] [Full Text] [Related]
12. Clinical application of recombinant erythropoietin in anemic cancer patients.
Henry DH
Hematol Oncol Clin North Am; 1994 Oct; 8(5):961-73. PubMed ID: 7852218
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer.
Limwattananon S; Limwattananon C; Maoleekulpairoj S; Soparatanapaisal N
J Med Assoc Thai; 2006 May; 89(5):690-8. PubMed ID: 16756057
[TBL] [Abstract][Full Text] [Related]
14. [Summary version of the Standards, Options and Recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology - Update 2003].
Spaeth D; Casadevall N; Daouphars M; Marchal C; Marec-Berard P; Fabre N; Haugh M;
Bull Cancer; 2004 Feb; 91(2):179-88. PubMed ID: 15047458
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis.
Scheetz MH; Bolon MK; Postelnick M; Noskin GA; Lee TA
J Antimicrob Chemother; 2009 Apr; 63(4):816-25. PubMed ID: 19202150
[TBL] [Abstract][Full Text] [Related]
16. Anemia therapy: individual benefit and societal cost.
Denton TA; Diamond GA; Matloff JM; Gray RJ
Semin Oncol; 1994 Apr; 21(2 Suppl 3):29-35. PubMed ID: 8202723
[TBL] [Abstract][Full Text] [Related]
17. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
18. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
Repetto L;
Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
[TBL] [Abstract][Full Text] [Related]
19. [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer].
Lastiri JM; Specterman SR; Rendo P; Pallotta MG; Varela MS; Goldstein S
Medicina (B Aires); 2002; 62(1):41-7. PubMed ID: 11965849
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
